• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Viridian Therapeutics Inc. (Amendment)

    2/13/24 5:17:30 PM ET
    $VRDN
    Medical Specialities
    Health Care
    Get the next $VRDN alert in real time by email
    SC 13G/A 1 tv02227-viridiantherapeutics.htm SCHEDULE 13G/A viridiantherapeuticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Viridian Therapeutics Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  92790C104

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  92790C104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    66,794

    7.  SOLE DISPOSITIVE POWER

    2,896,512

    8.  SHARED DISPOSITIVE POWER

    104,436

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,000,948

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.71%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Viridian Therapeutics Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    221 Crescent Street, Suite 401
    Waltham, MA 02453

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    92790C104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $VRDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VRDN

    DatePrice TargetRatingAnalyst
    12/10/2025$42.00 → $47.00Outperform
    Wedbush
    12/3/2025Outperform
    William Blair
    11/24/2025Buy
    Truist
    8/25/2025$44.00Buy
    Jefferies
    12/19/2024$37.00 → $27.00Overweight → Equal Weight
    Wells Fargo
    11/25/2024Buy
    TD Cowen
    9/11/2024$30.00 → $38.00Buy
    Needham
    6/11/2024$29.00Outperform
    Wolfe Research
    More analyst ratings

    $VRDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Tousignant Jennifer sold $70,796 worth of shares (2,272 units at $31.16), closing all direct ownership in the company (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    1/2/26 5:25:52 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Director Fairmount Funds Management Llc bought $9,999,990 worth of shares (454,545 units at $22.00) (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    10/27/25 4:30:38 PM ET
    $VRDN
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Cain Christopher W.

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    7/2/25 4:48:31 PM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $9,999,990 worth of shares (454,545 units at $22.00) (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    10/27/25 4:30:38 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Chief Operating Officer Beetham Thomas W. bought $117,050 worth of shares (5,000 units at $23.41), increasing direct ownership by 500% to 6,000 units (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    9/30/24 7:12:50 PM ET
    $VRDN
    Medical Specialities
    Health Care

    President and CEO Mahoney Stephen F. bought $499,262 worth of shares (21,400 units at $23.33) (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    9/30/24 7:10:58 PM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 16,650 shares of the company's common stock to one new employee (the "Inducement Grants") on January 2, 2026 (the "Grant Date"). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the "Plan") but remain subject to the terms and conditions of s

    1/8/26 4:01:00 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Prepares for Transformational 2026

    - Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track - - Topline phase 3 results for subcutaneous elegrobart (VRDN-003) on track for Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 for active and chronic TED, respectively - - IND submitted for half-life extended FcRn-inhibitor, VRDN-008; healthy volunteer (HV) data expected in 2H 2026 - - Unveiling new program targeting thyroid-stimulating hormone receptor (TSHR); IND expected Q4 2026 - - Cash position of approximately $888 million as of October 31, 2025 - - Company expects its current business plans to be funded through profita

    1/6/26 7:01:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

    - PDUFA target action date of June 30, 2026 - - Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in the safety or effectiveness of treating a serious condition - - Veligrotug now has both Priority Review and Breakthrough Therapy Designations, each following requests which included data on veligrotug's (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, toda

    12/22/25 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush reiterated coverage on Viridian Therapeutics with a new price target

    Wedbush reiterated coverage of Viridian Therapeutics with a rating of Outperform and set a new price target of $47.00 from $42.00 previously

    12/10/25 9:29:14 AM ET
    $VRDN
    Medical Specialities
    Health Care

    William Blair initiated coverage on Viridian Therapeutics

    William Blair initiated coverage of Viridian Therapeutics with a rating of Outperform

    12/3/25 8:40:59 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Truist initiated coverage on Viridian Therapeutics

    Truist initiated coverage of Viridian Therapeutics with a rating of Buy

    11/24/25 8:31:08 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    SEC Filings

    View All

    SEC Form 10-Q filed by Viridian Therapeutics Inc.

    10-Q - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

    11/5/25 7:57:29 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

    11/5/25 7:09:22 AM ET
    $VRDN
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by Viridian Therapeutics Inc.

    424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

    10/22/25 9:51:14 PM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Leadership Updates

    Live Leadership Updates

    View All

    Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

    - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye disease (TED), are on track for topline data in the first half of 2026 - - VRDN-006 clinical data in healthy volunteers on track for third quarter 2025 - - VRDN-008, a bispecific neonatal Fc receptor (FcRn) inhibitor with an extended half-life, on track for an Investigational New Drug (IND) submission for year-end 2025 - - Appointed Jeff Ajer, long-time Chief Commercial Officer of BioMarin, to Viridian's Board

    5/6/25 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

    - Mr. Ajer was most recently Chief Commercial Officer at BioMarin - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement, and sales operations. He most recently served as the Executive Vice President and Chief Commercial Officer (CCO) at BioMarin Pharmaceutical, where he joined in 20

    4/7/25 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

    - Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing Q4W or Q8W subcutaneous (SC) VRDN-003 in active and chronic TED, progressing as planned and on track for topline data for both trials in the first half of 2026 - - Proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter o

    2/27/25 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Financials

    Live finance-specific insights

    View All

    Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

    - Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global phase 3 study in patients with chronic TED to demonstrate a statistically significant and clinically meaningful 56% diplopia responder rate (placebo-adjusted rate of 31%, p = 0.0006) and 32% rate of diplopia complete resolution (placebo-adjusted rate of 18%, p = 0.0152) - - Veligrotug was generally well-tolerated with 94% of patients completing their treatment course and a 9.6% placebo-adjusted rate of hearing impairment - - BLA submission for veligrotug

    12/16/24 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

    - THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presenta

    12/13/24 6:00:00 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

    - Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of 70% and a placebo-adjusted PRR of 64% (p < 0.0001) - - All secondary endpoints were highly statistically significant (p < 0.0001), with clinically meaningful patient outcomes, including complete resolution of diplopia in 54% of patients (placebo-adjusted rate of 43%) and reduction of Clinical Activity Score (CAS) to 0 or 1 in 64% of patients (placebo-adjusted reduction of 46%) treated with veligrotug - - Veligrotug was generally well-tolerated with no treatment-r

    9/10/24 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 5:53:44 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 5:52:18 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 4:50:30 PM ET
    $VRDN
    Medical Specialities
    Health Care